Author
Listed:
- Coralie Dorard
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Charlène Estrada
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Céline Barbotin
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Magalie Larcher
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Alexandra Garancher
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Jessy Leloup
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Friedrich Beermann
(Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne)
- Manuela Baccarini
(Max F. Perutz Laboratories, Center for Molecular Biology, University of Vienna)
- Celio Pouponnot
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Lionel Larue
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Alain Eychène
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
- Sabine Druillennec
(Institut Curie
INSERM U1021, Centre Universitaire
CNRS UMR 3347, Centre Universitaire
Université Paris Sud-11)
Abstract
NRAS and its effector BRAF are frequently mutated in melanoma. Paradoxically, CRAF but not BRAF was shown to be critical for various RAS-driven cancers, raising the question of the role of RAF proteins in NRAS-induced melanoma. Here, using conditional ablation of Raf genes in NRAS-induced mouse melanoma models, we investigate their contribution in tumour progression, from the onset of benign tumours to malignant tumour maintenance. We show that BRAF expression is required for ERK activation and nevi development, demonstrating a critical role in the early stages of NRAS-driven melanoma. After melanoma formation, single Braf or Craf ablation is not sufficient to block tumour growth, showing redundant functions for RAF kinases. Finally, proliferation of resistant cells emerging in the absence of BRAF and CRAF remains dependent on ARAF-mediated ERK activation. These results reveal specific and compensatory functions for BRAF and CRAF and highlight an addiction to RAF signalling in NRAS-driven melanoma.
Suggested Citation
Coralie Dorard & Charlène Estrada & Céline Barbotin & Magalie Larcher & Alexandra Garancher & Jessy Leloup & Friedrich Beermann & Manuela Baccarini & Celio Pouponnot & Lionel Larue & Alain Eychène & S, 2017.
"RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma,"
Nature Communications, Nature, vol. 8(1), pages 1-13, August.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms15262
DOI: 10.1038/ncomms15262
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms15262. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.